UNSPSC 51162025: Ephedrine/phenobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162025 Ephedrine/phenobarbital is a Commodity code that in practice captures state and local procurement of pharmaceutical products and pharmacy services far broader than the code's nominal scope—recent opportunities show counties, state health agencies, and cooperative purchasing alliances buying naloxone and drug deactivation systems, on-site pharmacy services for employee health plans, generic pharmaceuticals and OTC products through multi-state cooperative agreements, and direct-to-manufacturer prescription fulfillment capabilities. The issuing bodies span county health departments (Seminole County, Florida; Hall County, Georgia), state health and human services commissions (Texas HHS Commission), and multi-state purchasing cooperatives (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon). Work being solicited ranges from tactical pharmaceutical procurement—naloxone and safe drug deactivation systems for community health initiatives, generic multi-source drugs and OTC products for state and local facilities—to strategic pharmacy services contracting, including on-site pharmacy operations for county employee health centers and exploratory direct-to-manufacturer prescription programs designed to bypass traditional pharmacy benefit managers and group purchasing organizations.

Recent activity concentrates in the Southeast and Upper Midwest, with documented opportunities in Florida, Georgia, Texas, and Minnesota. Representative recent solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (response deadline July 26, 2023); Hall County, Georgia's RFQ/P #47-010 for on-site pharmacy services at its Family Health Center Clinic serving approximately 3,005 eligible individuals under its group health insurance plans (response deadline June 4, 2026, with an 80/20 evaluation weighting technical qualifications at 80 percent and cost at 20 percent); Minnesota's MMCAP RFP for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to state and local facilities (proposals due March 26, 2026, with price competitiveness weighted at 75 percent); and Texas HHS Commission's exploratory RFI on direct-to-manufacturer prescription capabilities (response deadline April 3, 2026). The code shows active procurement velocity across both routine pharmaceutical supply and emerging service models, though the mismatch between the code's nominal scope and the actual pharmaceutical and pharmacy services work being bought suggests the code captures a wider pharmaceutical-procurement family than its name implies.